HIT THE MARK: A multi-stakeholder collaboration to drive equity for cancer biomarker testing and precision medicine was launched last March 21. L-R: Engr. Emer Rojas, President of New Vois Association of the Philippines; Melissa Ongsue, VP of Sales and Marketing at Hi Precision Diagnostics; Dr. Herdee Gloria Luna, President of Philippine Society of Oncologists; Dr. Jose Jasper Andal, pathologist from St.
After launching its first two pilots in Spain and Hungary last year, FT3 is trying to identify potential collaborative solutions and global best practices to these challenges through demonstration pilots and is now launching a local multi-stakeholder collaboration in the Philippines to work on solutions to improve patient outcomes.
Biomarker testing is a significant pillar of precision medicine, which uses patient data to inform personalized treatment decisions. Biomarker tests are essential tools in the diagnosis and treatment of cancer. They can be used to provide precise diagnoses and identify patients most likely to respond to treatment, therefore informing treatment selection. Personalized medicine can transform lives, but its potential benefits have not yet been fully realized.